ID: ALA1946962

Max Phase: Preclinical

Molecular Formula: C20H15BrF2N2O2S

Molecular Weight: 465.32

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)Cn1c2c(c3cc(F)ccc31)CCN(Cc1ccc(Br)cc1F)C2=S

Standard InChI:  InChI=1S/C20H15BrF2N2O2S/c21-12-2-1-11(16(23)7-12)9-24-6-5-14-15-8-13(22)3-4-17(15)25(10-18(26)27)19(14)20(24)28/h1-4,7-8H,5-6,9-10H2,(H,26,27)

Standard InChI Key:  CSWPBKIRCDOXDZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 465.32

Molecular Weight (Monoisotopic): 464.0006

AlogP: 4.50

#Rotatable Bonds: 4

Polar Surface Area: 45.47

Molecular Species: ACID

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 4.00

CX Basic pKa:

CX LogP: 4.70

CX LogD: 1.54

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.58

Np Likeness Score: -1.28

References

1. Minehira D, Takeda D, Urata H, Kato A, Adachi I, Wang X, Matsuya Y, Sugimoto K, Takemura M, Endo S, Matsunaga T, Hara A, Koseki J, Narukawa K, Hirono S, Toyooka N..  (2012)  Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1.,  20  (1): [PMID:22104435] [10.1016/j.bmc.2011.10.073]

Source

Source(1):

• Scientific Literature